自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体(mAb)以来,已过去四年多。如今,贝马妥珠单抗(bemarituzumab)的新数据证明了安进公司这一决策的正确性。6月30日,安进公司公布了一项胃癌III期临床试验的主要结果,显示该单克隆抗体达到了主要生存终点。尽管这家制药公司未透露此次临床试验成功的具体细节,但承诺会在未来的医学会议上提供详细数据。这项名为...
Source Link自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体(mAb)以来,已过去四年多。如今,贝马妥珠单抗(bemarituzumab)的新数据证明了安进公司这一决策的正确性。6月30日,安进公司公布了一项胃癌III期临床试验的主要结果,显示该单克隆抗体达到了主要生存终点。尽管这家制药公司未透露此次临床试验成功的具体细节,但承诺会在未来的医学会议上提供详细数据。这项名为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.